Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Health Case for Reforming the Toxic Substances Control Act: April 21

The American Association on Intellectual and Developmental Disabilities is hosting an installment of its Environmental Health Initiative Policy Webinar Series on April 21 from 2:00 p.m to 3:00 p.m. The webinar will feature Charlotte Brody, director of chemicals and chemical policy for the Blue Green Alliance who will discuss a recent publication of the Safer Chemicals, Healthy Families coalition, "The Health Case for Reforming the Toxic Substances Control Act." According to the webinar announcement, the publication "details the growing scientific literature linking chemical exposures to six categories of chronic conditions … It [also includes estimates of] the portion of our disease burden that is attributable to chemical exposures and the potential health cost savings from improved protection from toxic chemicals." For more information, go to: www2.gotomeeting.com/register/772398507

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG007983

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel